Subcutaneous versus intravenous immunoglobulin for chronic autoimmune neuropathies

Naddaf, Elie; Murad, M. Hassan; Dyck, P. J.

doi:10.1002/mus.25643

Cited by 3 publications

(1 citation statement)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The major challenge with SCIg is skin irritation, which is dose‐dependent, but also seems to lessen with time 63 . It is safe and reasonable to consider switching from IVIg to SCIg for convenience, poor intravenous access, end‐of‐dose wear‐off effect, or adverse events with intravenous infusions 64 . However, before switching, patients must be stable on IVIg, as there is currently insufficient evidence for SCIg as inductive therapy in treatment‐naive CIDP patients.…”

Section: Existing Therapies: Standard Of Practice and Comparative Effmentioning

confidence: 99%

Chronic inflammatory demyelinating polyradiculoneuropathy—Diagnostic pitfalls and treatment approach

2020

Self Cite

View full text Add to dashboard Cite

Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is characterized by progressive weakness and sensory loss, often affecting patientsʼ ability to walk and perform activities of daily living independently. With the lack of a diagnostic biomarker, the diagnosis relies on clinical suspicion, clinical findings, and the demonstration of demyelinating changes on electrodiagnostic (EDx) testing and nerve pathology. As a result, patients can often be misdiagnosed with CIDP and unnecessarily treated with immunotherapy. Interpreting the EDx testing and cerebrospinal fluid findings in light of the clinical phenotype, recognizing atypical forms of CIDP, and screening for CIDP mimickers are the mainstays of the approach to patients suspected of having CIDP, and are detailed in this review. We also review the currently available treatment options, including intravenous immunoglobulin (IVIg), corticosteroids (CCS), and plasma exchange (PE), and discuss how to approach treatment‐refractory cases. Finally, we emphasize the need to adopt objective outcome measures to monitor treatment response.

show abstract

Section: Existing Therapies: Standard Of Practice and Comparative Effmentioning

confidence: 99%